Neuronetics Inc. (NASDAQ:STIM) shares soared 41.08% to $2.06 in after-hours trading on Tuesday following preliminary fourth-quarter 2025 financial results.
Revenue Climbs Across Both Segments
The medical technology company reported fourth-quarter 2025 revenue of $41.8 million, up 23% on an adjusted pro forma basis and 86% compared with fourth-quarter 2024 on an as-reported basis.
Revenue from the NeuroStar system, the first transcranial magnetic stimulation (TMS) device to receive Food and Drug Administration clearance, was $18.3 million, up 9% pro forma, while clinic revenue reached $23.5 million, up 37% pro forma.
According to the company, it shipped 49 NeuroStar Advanced Therapy systems and generated positive operating cash flow of $0.9 million during the quarter, in line with previously issued guidance.